Induction of immunity against experimental Chlamydia pneumoniae infection
نویسندگان
چکیده
..........................................................................................................................7 1. REVIEW OF THE LITERATURE ............................................................................................8 1.1. Vaccines against intracellular microbes.............................................................................. 8 1.2. Chlamydiae, common human pathogens ............................................................................. 8 1.2.1. Chlamydiae..................................................................................................................... 8 1.2.2. Acute infection caused by C. pneumoniae .................................................................... 11 1.2.3. Chronic infection caused by C. pneumoniae ................................................................ 12 1.3. Vaccination against C. pneumoniae ................................................................................... 13 1.3.1. History of Chlamydial vaccine ..................................................................................... 13 1.3.2. The correlates of protective immunity to C. pneumoniae............................................. 16 1.4. Vaccines inducing cellular immunity ................................................................................ 21 1.4.1. General requirements ................................................................................................... 21 1.4.2. DNA vaccines ............................................................................................................... 21 1.4.3. Viral vectors ................................................................................................................. 23 1.4.4. Heterologous prime-boost regimens............................................................................. 25 1.5. Antigenic proteins of C. pneumoniae possible vaccine candidates............................... 26 1.5.1. Outer membrane proteins............................................................................................. 27 1.5.2. Inclusion membrane proteins (Incs) ............................................................................. 29 1.5.3. Type III secretion system (TTSS) .................................................................................. 29 1.5.4. Heat shock proteins (Hsps)........................................................................................... 30 2. AIMS OF THE STUDY......................................................................................................32 3. MATERIALS AND METHODS..........................................................................................33 4. RESULTS AND DISCUSSION...........................................................................................37 4.1. Selection of ORFs ................................................................................................................ 37 4.2. Production of C. pneumoniae proteins in B. subtilis (I, IV) ............................................. 38 4.3. Utilization of C. pneumoniae recombinant proteins in immunological assays (I, IV) ... 39 4.3.1. Assays for CMI ............................................................................................................. 39 4.3.2. Use of recombinant C. pneumoniae proteins in characterization of murine systemic and mucosal antibody response after infection.............................................................................. 39 4.4. DNA immunization against C. pneumoniae in mice (II) .................................................. 42 4.4.1. In vitro protein expression............................................................................................ 43 4.4.2. Immune response to immunization ............................................................................... 44 4.4.3. Response to challenge .................................................................................................. 45 4.5. DNA priming and rSFV boosting (III) .............................................................................. 45 4.5.1. In vitro protein expression............................................................................................ 47 4.5.2. Immune response to immunization ............................................................................... 47 4.5.3. Response to challenge .................................................................................................. 48 4.6. Why only partial protection was achieved? ...................................................................... 50 5. CONCLUDING REMARKS AND FUTURE PROSPECTS ....................................................53 6. ACKNOWLEDGEMENTS................................................................................................54 7. REFERENCES..................................................................................................................55 Induction of immunity against experimental Chlamydia pneumoniae infection 4 List of original publications This thesis is based on the following original articles referred to in the text by their Roman numerals. The articles in this thesis have been reproduced with the permission of the copyright holders. In addition, some unpublished data are presented. I Airaksinen U, Penttilä T, Wahlström E, Jackson L, Vuola JM, Puolakkainen M and Sarvas M (2003). Production of Chlamydia pneumoniae proteins in Bacillus subtilis and their use in characterizing immune responses in the experimental infection model. Clin and Diag Lab Immunol 10:367-375. II Penttilä T, Vuola JM, Puurula V, Anttila M, Sarvas M, Rautonen N, Mäkelä PH and Puolakkainen M (2000). Immunity to Chlamydia pnemoniae induced by vaccination with DNA vectors expressing the cytoplasmic protein (Hsp60) or outer membrane proteins (MOMP and Omp2). Vaccine 19:1256-1265. III Penttilä T*, Tammiruusu A*, Liljeström P, Sarvas M, Mäkelä PH, Vuola JM and Puolakkainen M (2004). DNA immunization followed by a viral vector booster in a Chlamydia pneumoniae mouse model. Vaccine 22:3386-3394. * equal contribution IV Penttilä T, Wahlström E, Vuola JM, Sarvas M and Puolakkainen M. Systemic and local antigen-specific antibody response in murine Chlamydia pneumoniae infection (submitted). Induction of immunity against experimental Chlamydia pneumoniae infection 5
منابع مشابه
Chlamydia pneumoniae and hyperlipidemia are co-risk factors for atherosclerosis: infection prior to induction of hyperlipidemia does not accelerate development of atherosclerotic lesions in C57BL/6J mice.
Chlamydia pneumoniae has been shown to accelerate atherosclerotic lesion development in hyperlipidemic animals. This study showed that C. pneumoniae did not accelerate lesion development in mice if a high-fat/high-cholesterol diet was started after infection, indicating that C. pneumoniae is a co-risk factor with hyperlipidemia for cardiovascular disease.
متن کاملبررسی فراوانی عفونت کلامیدیا پنومونیه در نسج آدنوئید کودکان آدنوئیدکتومی شده در مجتمع حضرت رسول اکرم(ص) تهران، 85-1384
Background & Aim: Recurrent or chronic adenotonsillar infections mainly affect children. The prevalence of potential respiratory pathogens on the adenoid and tonsillar surfaces of children with moderate symptoms of recurrent tonsillopharyngitis and/or adeno tonsillar hypertrophy differs only slightly from that in children without symptoms of adenotonsillar disease. Chlamydia pneumoniae is a...
متن کاملA mouse model of Chlamydia pneumoniae strain TWAR pneumonitis.
Chlamydia pneumoniae is a common cause of acute respiratory infections in humans. We evaluated mice as experimental animals for C. pneumoniae. Intranasal inoculation of Swiss Webster mice with C. pneumoniae induced a prolonged course of lung infection, as demonstrated by reisolation of organisms from lungs (at 42 days) and persistence of lung pathology (> 60 days). The lung pathology was charac...
متن کاملCell-mediated immune response during primary Chlamydia pneumoniae infection.
The development of Chlamydia pneumoniae-specific cell-mediated immunity was studied during a primary C. pneumoniae infection. The immune response was detected as positive lymphocyte proliferation and secretion of interferon gamma. C. pneumoniae-induced activation of both CD4(+) and CD8(+) T cells was detected in the early phase of infection, but activation of only CD4(+) T cells was detected in...
متن کاملExposure to mycobacteria primes the immune system for evolutionarily diverse heat shock proteins.
During stress conditions, such as infection, the synthesis of heat shock proteins (HSPs) in microorganisms is upregulated. Since a high degree of homology exists within each HSP family, we postulated that exposure to microorganisms could prime the immune system for evolutionarily diverse HSPs. We tested this hypothesis by priming mice with three microorganisms, namely, Mycobacterium bovis BCG, ...
متن کامل